five

Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy

收藏
NIAID Data Ecosystem2026-03-07 收录
下载链接:
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2144788
下载链接
链接失效反馈
官方服务:
资源简介:
This is an open-label phase III study of regorafenib in patients with metastatic colorectal cancer (mCRC) who have progressed after all approved standard therapy. The purpose of this study is to provide additional information about the safety profile of Regorafenib.
创建时间:
2013-07-15
二维码
社区交流群
二维码
科研交流群
商业服务